DiaMedica Therapeutics Inc. (NASDAQ:DMAC) will release earnings for its fourth quarter after the closing bell on Monday, March 30.
Analysts expect the Minneapolis, Minnesota-based company to report quarterly loss of 18 cents per share. That’s the same as the 18 cents loss recorded in the year-ago period, according to Benzinga Pro.
On March 5, DiaMedica Therapeutics received Health Canada clearance to initiate Phase 2 study of DM199 in Preeclampsia.
Shares of DiaMedica Therapeutics fell 0.9% to close at $6.79 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- Cantor Fitzgerald analyst Josh Schimmer initiated coverage on the stock with an Overweight rating and a price target of $25 on Nov. 14, 2025. This analyst has an accuracy rate of 69%.
- HC Wainwright & Co. analyst Matthew Caufield maintained a Buy rating with a price target of $12 on Aug. 15, 2025. This analyst has an accuracy rate of 72%.
- Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating and raised the price target from $8 to $11 on July 18, 2025. This analyst has an accuracy rate of 77%.
- Lake Street analyst Thomas Flaten maintained a Buy rating and increased the price target from $11 to $14 on July 18, 2025. This analyst has an accuracy rate of 48%.
Considering buying DMAC stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments